
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇸🇦SA · Entrepreneurship#198500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
250 to 1.5K🎙 ~2x weekly·48 episodes·Last published 2d ago - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇸🇦100% - Active Followers
Loyal subscribers who consistently listen
150 to 900
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 13 epsHosts
Recent guests
Recent episodes
The Myocarditis Double Standard: COVID, the Vaccine, and the Pediatric Deaths That Went Unreported
Jul 2, 2026
Unknown duration
David Zweig on Schools, Science, and the Media's COVID Failure
Jun 27, 2026
Unknown duration
Drug Pricing, Broken Incentives, and the 340b program Fixes Washington Won't Touch
Jun 20, 2026
Unknown duration
Dr. Sanjay Dhall on Trauma, Medical Training, and the County Hospital That Doesn’t Bill
Jun 13, 2026
Unknown duration
The Atom Bomb Speaks: Tracy Høeg on COVID, Myocarditis, and the FDA From the Inside
Jun 10, 2026
1h 13m 25s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/2/26 | ![]() The Myocarditis Double Standard: COVID, the Vaccine, and the Pediatric Deaths That Went Unreported | Episode SummaryDr. Tracy Beth Høeg returns alongside Dr. Venkatesh Murthy, NIH-funded cardiologist at the University of Michigan, to dissect the Senator Ron Johnson congressional memo detailing pediatric deaths following COVID-19 vaccination — deaths the FDA's own pharmacovigilance team flagged internally but never disclosed publicly. The conversation covers the well-documented double standard applied to COVID myocarditis versus vaccine myocarditis, how journal editors killed papers not for scientific flaws but out of fear of social media backlash, why Korea's autopsy data revealed fatal cases that would never have been identified otherwise, the post-marketing commitment failures by Pfizer and Moderna, and what it means that we are still annually approving a vaccine with no randomized controlled trial evidence of clinical benefit in the current immune landscape.Chapter Markers00:00 Introduction: Why Dr. Høeg Is Back and What the Ron Johnson Memo Reveals02:03 How Vaccine Myocarditis First Surfaced: Israel, the U.S. Military, and Early Warning Signs05:36 Dr. Murthy on the Biology: Why the mRNA Vaccine Produced Cardiac Inflammation in a Different Population Than Expected10:36 The Puntmann Paper: Statistical Problems, Confounding, and the Push to Close Schools and Cancel Sports13:58 The Double Standard in Real Time: Subclinical MRI Findings vs. Kids Presenting With Chest Pain16:26 Risk-Benefit Mismatch: Vaccine Myocarditis in Young Males vs. Genuine COVID Risk in That Population21:05 Dr. Høeg's VAERS Analysis: Rates of One in Five Thousand, What the FDA's Own Data Showed, and the Paper That Almost Never Ran24:03 Dr. Murthy Reveals: He Was a Reviewer for a Journal That Killed This Paper for Political Reasons28:23 Inconsistency of Vaccine Skeptics: Who Was Questioning the Trials Before Election Day35:52 Korea's Autopsy Program and Why the U.S. Has No Comparable Surveillance System40:21 The Chikungunya Vaccine Withdrawal: One Death, One Action — and the Contrast With COVID42:34 Inside the FDA: The OBPV Memo, the 10 Probable/Possible Deaths in Children, and What Happened Next53:30 Senator Johnson's Subpoena and Why the Number Dropped from 10 to 758:20 Causal Attribution Double Standard: COVID Deaths vs. Vaccine Deaths1:20:59 Should the COVID Vaccine Still Be Approved? Dr. Høeg on the Absence of Clinical Efficacy Evidence1:23:31 The CDC-Blocked Study, Healthy Vaccinee Bias, and the Limits of Observational Data1:28:08 What FDA Approval Actually Means — and What It Should MeanCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod | — | ||||||
| 6/27/26 | ![]() David Zweig on Schools, Science, and the Media's COVID Failure | Episode SummaryInvestigative journalist David Zweig joins Anish Koka and Anthony DiGiorgio to discuss his book An Abundance of Caution: American Schools, The Virus, and a Story of Bad Decisions — a heavily cited account of how public health authorities, the media, and a politically homogenous expert class got COVID policy badly wrong, especially for children. The conversation covers why U.S. media coverage was uniquely alarmist compared to the rest of the world, how Americans overestimated child COVID mortality by as much as 40 times, the role of "technological solutionism" in making school closures possible when they never would have been before, and what it would actually take to rebuild public trust in institutions that squandered it. The episode opens with a discussion of MidJourney's foray into medical imaging and what it reveals about AI hype cycles in medicine.Resource:David's Book: https://www.amazon.com/Abundance-Caution-American-Schools-Decisions/dp/0262053993Chapter Markers00:00 Welcome and intro: David Zweig01:14 MidJourney enters medical imaging — hype or breakthrough?05:35 Incidentalomas, cash-pay scanning, and who bears the cost08:55 Ultrasound physics and why AI won't replace radiologists yet14:00 Transition to the book: An Abundance of Caution17:00 The Twitter Files and Zweig's COVID journalism23:00 Political monoculture in public health and legacy media41:43 Sweden, BLM protests, and the shifting COVID rules43:06 The empirics on children: what the data actually showed50:29 American media's uniquely alarmist pandemic coverage56:31 Living in a deep blue area: why data couldn't penetrate the narrative58:18 Anthony's ICU story and the Gellman Amnesia moment59:50 How do we rebuild trust in public health?1:08:28 Technological solutionism: why school closures were impossible before Zoom1:10:07 1950s flu epidemics — schools stayed open with 50% of kids out sick1:25:20 Newsroom monoculture, book publishing, and the conservative imprint problem1:28:08 Reforming institutions vs. questioning their foundations1:36:39 Wrap-up: the pandemic as a case study in how society functionsCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod | — | ||||||
| 6/20/26 | ![]() Drug Pricing, Broken Incentives, and the 340b program Fixes Washington Won't Touch | Episode SummaryRyan Long — former senior policy advisor to Speaker Kevin McCarthy and current non-resident senior scholar at the USC Schaefer Institute — joins Drs. Koka and DiGiorgio for a deep dive into the structural failures driving American drug pricing. The conversation covers the list-to-net price bubble and why patients pay cost-sharing on a fictitious number, how the IRA's price-setting mechanism disincentivizes both new drug development and subsequent indications, and why the 340B program — sold politically as a lifeline for safety net hospitals — systematically funnels the most money to wealthy health systems with high commercial payer mixes. Long argues the fix isn't tweaking the formula; it's scrapping the drug arbitrage mechanism entirely and replacing it with a direct, transparent grant program that actually reaches the hospitals that need it.Chapter Markers00:00 Introduction — Ryan Long's 25 Years in Health Policy02:08 Drug Pricing 101: List Price vs. Net Price and Why It Matters06:39 GLP-1s as a Case Study: Insurance Pullback and the Price War That Followed11:17 The Medicare Bridge Program and Government Price Setting for GLP-1s14:11 Why Drug Companies Set List Prices High at Launch16:10 The Inflation Reduction Act: Price Controls, Rebate Penalties, and Innovation Risk20:57 Brand-to-Brand Competition and the FDA's Role28:52 GLP-1s Under Medicare: Is the $50/Month Bridge Program Good Policy?36:50 The Medicaid Drug Rebate Program and the Best Price Provision38:08 The Origins of 340B: What the Program Was Actually Designed to Do42:24 Qui Bono — How 340B Revenue Is Really Generated50:17 Contract Pharmacies and the For-Profit Middlemen in 340B56:31 The Humira Biosimilar Case and the Rebate Trap1:02:58 The 1987 Supreme Court Case That Supercharged the Rebate Structure1:05:26 Broad Reform Proposals: From 340B Overhaul to Consolidation1:09:19 Closing Thoughts and Where to Find Ryan's WorkCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod | — | ||||||
| 6/13/26 | ![]() Dr. Sanjay Dhall on Trauma, Medical Training, and the County Hospital That Doesn’t Bill | Episode SummaryThis week, Drs. DiGiorgio and Koka are joined by returning guest Dr. Sanat Dixit and special guest Dr. Sanjay Dhall, chief of neurosurgery at Harbor-UCLA and a leading spinal cord injury researcher. Dr. Dhall traces his path from a "commando shift" in a Houston trauma bay as a pre-med student to running solo trauma call at Grady Hospital as a young attending, then discusses the strange reality of his current institution: a major county hospital that doesn't bill professional fees or for implants, leaving millions on the table. The conversation moves through hospital alignment under for-profit versus non-profit models, the Christopher Duntsch case and what it reveals about resident training and the GME system, Dr. Dhall's controversial Wall Street Journal letter on NIH indirect costs, and a guideline fight over early surgery for spinal cord injury that got him removed from a neurosurgery executive committee. The episode closes with a wide-ranging discussion on AI and robotics in surgery — what they might realistically take off physicians' plates, and what they almost certainly can't replace.Chapter Markers00:00 Welcome and introducing Dr. Sanjay Dhall01:49 From a Houston "commando shift" to a trauma bug05:10 Running Grady's trauma service solo as the only neurosurgeon09:25 The unsupervised resident era and its billing aftershocks14:03 Harbor-UCLA doesn't bill for neurosurgery profies — or implants19:44 How county hospitals account for six-figure implant write-offs24:30 Fiduciary duty, taxpayers, and the case for billing aggressively28:00 Drug rep economics at county hospitals31:10 Comparing Cleveland Clinic, Mayo, and the county model34:29 The "color-coded sticker" idea and the bureaucratic mindset37:59 For-profit alignment vs. "non-profits functioning as for-profits"43:24 The Devi Shetty suture story and physician-driven cost control44:13 Physician ownership, conflicts of interest, and carve-out hospitals46:00 Jefferson's neuro hospital and the private anesthesia advantage48:45 The Christopher Duntsch case and a failure of training oversight52:10 How does an incompetent surgeon make it through residency?56:04 Troubled personalities in neurosurgery training1:00:04 Work-hour restrictions and the self-selection of old-school neurosurgery1:02:29 Is dissent tolerated in academic medicine anymore?1:06:31 Inside NIH indirect costs — where 40-60% of grant money goes1:10:19 The spinal cord injury guideline fight and getting removed from committee1:13:44 Burnout, call coverage, and the safety net argument1:20:27 Will robots ever do neurosurgery?1:23:11 AI for administrative burden vs. AI in the OR1:28:34 The pilot analogy, a ruptured aneurysm story, and the limits of automationCo-Host Handles@anish_koka and @drdigiorgioShow Handle@drsloungepodSubscribe LinksSpotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrRApple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658YouTube: https://www.youtube.com/@TheDoctorsLoungePod | — | ||||||
| 6/10/26 | ![]() The Atom Bomb Speaks: Tracy Høeg on COVID, Myocarditis, and the FDA From the Inside✨ | COVID-19myocarditis+4 | Tracy Høeg | FDANIH | — | COVID-19myocarditis+5 | — | 1h 13m 25s | |
| 6/6/26 | ![]() The ER Doc Who Quit the System - and Built His Own✨ | emergency medicinedirect care+4 | Dr. Noah Kaufman | Cough CareAmerican Ninja Warrior | — | emergency physicianCough Care+7 | — | 1h 02m 16s | |
| 6/3/26 | ![]() The Cholesterol Debate: What the Keto Influencers Get Right (and Wrong)✨ | cholesterol debatelow-carb diet+4 | Dr. Greg Katz | NYU LangoneBeyond Journal Club | — | cholesterolKeto diet+5 | — | 1h 00m 57s | |
| 5/31/26 | ![]() Gaming the System: LTACHs, Guidelines, and the Evidence Problem in American Medicine✨ | American healthcarelong-term acute care hospitals+4 | Dr. Anil Makam | UCSFZuckerberg San Francisco General+2 | — | LTACHhealthcare+5 | — | 1h 05m 19s | |
| 5/25/26 | ![]() The FDA, Unicure, and the Limits of Accelerated Approval✨ | FDA approvalgene therapy+4 | Adu | AMT-130FDA+8 | — | FDAUnicure+7 | — | 53m 09s | |
| 5/23/26 | ![]() Salty About Medical Education: Bryan Carmody on What the System Gets Wrong✨ | medical educationphysician shortage+4 | Bryan Carmody | AAMCERAS+1 | — | medical educationphysician shortage+6 | — | 1h 07m 36s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/17/26 | ![]() Free Markets, Private Equity, and the Moral Case for Medicine✨ | healthcare policyfree markets+5 | Jared Rhoads | Center for Modern HealthDartmouth Institute+3 | — | healthcare policyfree markets+5 | — | 1h 26m 47s | |
| 5/16/26 | ![]() George Tolis: TAVR, Broken Training, and What's Really Wrong With Cardiac Surgery.✨ | cardiac surgeryTAVR+4 | George Tolis | Brigham and Women's Hospital | — | TAVRcardiac surgery+5 | — | 1h 11m 06s | |
| 5/10/26 | ![]() Center-Right in a White Coat: Pradeep Shanker on AI, Vaccines, and Medical Orthodoxy✨ | AI in radiologyCOVID policy+4 | Pradeep Shanker | AduhelmNational Review+2 | — | radiologyAI+5 | — | 1h 16m 10s | |
| 5/3/26 | ![]() The Surgeon Who Refused to Bow: Dr. Eithan Haim on Blowing the Whistle at Texas Children's✨ | whistleblowingpediatric gender medicine+3 | Dr. Eithan Haim | Texas Children's HospitalTexas Children's+2 | — | whistleblowerTexas Children's Hospital+5 | — | 1h 24m 17s | |
| 5/2/26 | ![]() From Babylon to Baylor: How Insurance Went Off the Rails✨ | history of insurancehealthcare policy+4 | AnishDr. DiGiorgio | BaylorLloyd's of London+2 | BabylonLondon | insurance historyhealthcare+6 | — | 34m 01s | |
| 4/26/26 | ![]() Outpatient Brain Surgery: How Buffalo Built America's Only Neurosurgical ASC✨ | neurosurgeryoutpatient surgery+3 | Dr. Elad Levy | University at BuffaloAtlas Surgery Center+2 | BuffaloPitt | neurosurgeryoutpatient surgery+6 | — | 50m 57s | |
| 4/25/26 | ![]() The Intellectual Case Against Medicare: Buchanan, Tullock, and the Rules of the Game✨ | Medicarepublic choice theory+4 | Dr. DiGiorgio | AMAMedicare+2 | — | Medicarepublic choice theory+6 | — | 37m 12s | |
| 4/19/26 | ![]() Rural Health Myths, Mark Cuban's HSA Gambit, and How Neurocritical Care Was Born | Back from hiatus, Anish and Dr. DiGiorgio swap travel notes on Japan and San Diego before diving into Anish's recent Substack piece mapping emergency cardiac care access across the United States — where 98% of Americans live within 90 minutes of a PCI-capable hospital, a level of coverage no peer country (including Canada) comes close to matching. They extend the analysis to thrombectomy-capable stroke centers, trauma coverage, and what it really means when the Commonwealth Fund ranks the US last. The conversation turns to whether the "rural healthcare crisis" narrative justifies continued subsidies (critical access designation, 340B, DISH payments, the new OBBA rural fund) or simply props up a monopoly structure that blocks physician-owned hospitals and ASCs. They unpack Mark Cuban's HSA-plus-catastrophic-coverage proposal, its blind spots on chronic illness and supply-side cost, the two-midnight rule lawsuit between Jefferson and Aetna, cost-plus reimbursement grandfathering, and how CMS's new "efficiency adjustment" has made it financially rational for neurosurgeons to hand off post-op critical care — inadvertently telling the origin story of neurocritical care as a specialty. They close with the new CDC director announcement and a look ahead to next week's guest, Dr. Elad Levy.00:00 Back from hiatus — Japan, San Diego, and American public transit03:45 Happy tax day and the Bay Area commute problem04:45 Anish's Substack piece: mapping PCI access across America07:50 Why PCI capability is the right proxy for emergency care infrastructure10:00 Building the map — counties, census tracts, and the 90-minute door-to-balloon window14:30 98% coverage: the US vs Canada, Russia, China18:24 Thrombectomy-capable stroke centers and the 60-minute brain window22:07 What do you actually want from a healthcare system?27:12 The original sin of Medicare and the employer tax exemption30:13 Rural hospital subsidies: critical access, 340B, DISH, and the OBBA rural fund37:02 Physician-owned hospitals, Stark Law, and ASCs as an alternative model40:30 Mark Cuban's HSA plan: stop-loss, direct primary care, and the $2,100 family premium44:13 Extending the idea to Medicaid — wealth accrual and the 100% benefit cliff46:31 The chronic illness problem and federal reinsurance as a backstop47:57 The missing piece: supply-side deregulation and lowering cost of care50:19 Jefferson sues Aetna: the two-midnight rule and who the real villain is53:04 UCR, cost-plus reimbursement, and the hospitals still grandfathered in55:37 The CMS efficiency adjustment and the neurosurgeon's 8-day break-even58:45 The origin story of neurocritical care as a specialty01:02:16 New CDC director Erica Schwartz and next week's guest Dr. Elad Levy@anish_koka and @drdigiorgio@drsloungepodResources:Quantifying the Rural Access Problem: Emergency Cardiac Care as a Window into American Healthcare — https://anishkokamd.substack.com/p/quantifying-the-rural-access-problemAmerica Has Solved the Hardest Healthcare Access Problem Better Than Anyone Else — Here's the Data — https://anishkokamd.substack.com/p/the-us-healthcare-system-has-basicallyInteractive PCI Access Maps (US & Canada) — https://anishkoka.github.io/pci-access-maps/YouTube: https://www.youtube.com/@TheDoctorsLounge | — | ||||||
| 4/3/26 | ![]() From Tehran to the C-Suite: Biotech CEO Ali Mortazavi on AI, Drug Discovery, and the Me-Too Problem | Guest: Ali Mortazavi | CEO, Tangram Therapeutics (formerly E-Therapeutics), London, UKEpisode Summary:Ali Mortazavi is not your typical biotech CEO. A computer scientist by training, former professional chess player, and veteran of financial markets, he invested in an RNAi company in 2012 — and then, by his own admission, made the crazy decision to become its CEO with zero background in biology, chemistry, or medicine.What followed is a 14-year education in the brutal realities of drug development — and a front-row seat to the AI revolution now reshaping it. In this wide-ranging conversation, Mortazavi draws on his extraordinary personal story (fleeing revolutionary Iran as a child, arriving in London unable to speak English, rising through chess and finance) to offer a uniquely cross-disciplinary perspective on why biotech is stuck in a me-too loop, why the incentive system is the real bottleneck, and where AI is — and isn't — changing the game.0:00 - Introduction & Ali's Background1:07 - The Iranian Revolution at Nine Years Old4:44 - Fleeing Iran, Arriving in London6:38 - The Refugee Experience and Starting Over7:49 - Computer Science in 19909:53 - Becoming a Professional Chess Player11:06 - The Vishwanathan Anand Moment13:17 - From Chess to Finance to Biotech CEO14:44 - The Gleevec Illusion and the Reality of Drug Development16:07 - Jay Bhattacharya, Reproducibility, and the PubMed Button18:18 - LLMs as Scientific Compression Systems20:15 - Why LLMs Give "The Average Answer" — The Co-Pilot Model23:44 - Vibe Coding and the Explosion of Code25:36 - AI Won't Replace 10x Coders — It Will Replace 90 of 10026:16 - The GalNAC Case Study: 35 Years of Forgotten Innovation31:10 - The Me-Too Algorithm and Biotech VC Incentives34:40 - GLP-1s: Another 30 Years of Sitting Around35:26 - The FDA, the XBI, and the Current Regulatory Landscape40:43 - Can Politics Fix the Incentive System?42:09 - Why Past Progress Happened Without AI44:24 - Medical Ethics, Experimentation, and the Innovation Tradeoff48:34 - Biotech Is Archaic: The Preclinical De-Risking Problem50:05 - No Animal Model Actually Works52:16 - Over-Regulation vs. Just Plain Hard53:00 - The US Market as the Global Subsidy Engine54:05 - China: Wake-Up Call, Not Innovator56:25 - The London Market: "Don't Call It a Market"58:52 - AI-Native Biotechs: Too Soon to Tell59:36 - Where AI Works: Information. Where It Doesn't: Physics.1:01:29 - Tangram Therapeutics and Libra OS1:04:25 - The Future: SaaS Collapse, Medicine Returns to Fundamentals1:07:36 - Closing: Hope, Broken Glass, and Early AdoptionSubscribe to The Doctor's Lounge: Apple Podcasts | Spotify | YouTube | RSSFollow the Show: X: @DrsLoungePodFollow the Guest: X: @AAMortazaviCo-hosts: @anish_koka | @drdanchoi | @dutchrojas | @sdixitmd | @drdigiorgio | — | ||||||
| 3/31/26 | ![]() Dr. DiGiorgio Goes to Washington: Site Neutrality, Stark Law Physician-Owned Hospitals & More | Episode SummaryDr. DiGiorgio returns from testifying before the House Energy and Commerce Subcommittee on Health, the third in a series of hearings on healthcare costs covering the provider landscape. The two break down the major policy levers discussed in his testimony — site-neutral payment, Stark Law reform, physician-owned hospitals, and Certificate of Need laws — and why so many obviously good solutions remain politically untouchable. They also dig into the rural access gap, the failure of the NP independence experiment to solve it, Medicare Advantage risk adjustment, and the new HHS healthcare advisory committee. As always, the diagnosis is clear; the politics are the hard part.Chapter Markers0:00 – Welcome back & Dr. DiGiorgio's Congressional testimony3:16 – Site-neutral payment: why everyone knows it's right and no one acts6:26 – You can't do site neutrality without also enabling competition8:20 – How MedPAC's methodology actually works11:50 – Stark Law explained — and why it creates a double standard14:32 – Hospice fraud, Armenian gangs, and Nick Shirley20:30 – The original sin: third-party payment and utilization control23:52 – The case for allowing physician referral networks25:15 – Hospitals' self-referral hypocrisy and the Federation of American Hospitals tweet28:52 – How Section 6001 of the ACA banned physician-owned hospitals30:13 – The new HHS healthcare advisory committee — will it matter?37:44 – The rural access gap: how big is the problem really?42:52 – Why NP independence didn't solve rural shortages47:58 – International medical graduates and the rural fiction50:06 – Let prices rise: the market solution to rural primary care55:25 – Medicaid federal matching rates and state competitiveness56:38 – How Democrats and Republicans engaged at the hearing58:57 – The politics of why nothing gets doneLinks:YouTube Dr. Digiorgio Congressional Testimony: https://www.youtube.com/watch?v=sjPr3fK9jjcWritten Testimony@anish_koka | @drdigiorgio@drsloungepod🎧 Spotify | Apple Podcasts | YouTube | — | ||||||
| 3/15/26 | ![]() The Cost of Dissent: How a Viral Newsweek Op-Ed Led to Medical School Dismissal | Kevin Bass, PhD, joins Anish and Dr. DiGiorgio to tell the story of how a viral Newsweek op-ed apologizing for his support of COVID lockdowns and mandates set off a chain of events that ended in his dismissal from Texas Tech's MD/PhD program. Kevin walks through the internal emails, sham professionalism hearings, and rigged dismissal process he uncovered through FERPA records requests — and his ongoing federal and state lawsuits alleging First Amendment retaliation. The conversation then shifts to what Kevin has been building since: using AI pipelines to do large-scale investigative data analysis, from parsing the Epstein files to probing Medicaid fraud — work he argues would have taken a newsroom months, done now in days by one person.YouTube Chapters:00:00 - Introduction and Kevin Bass background01:16 - Kevin's COVID arc: from establishment supporter to dissenter03:14 - The Newsweek op-ed and Tucker Carlson appearance08:00 - Internal emails and the professionalism complaint campaign13:44 - Sham hearings, appeals, and eventual dismissal19:19 - The rigged consolidated hearing and Darren Gibson27:34 - Dr. DiGiorgio on the medical training dismissal system29:51 - Why Kevin still believes in the broader legal system33:00 - What Kevin has been building since dismissal36:00 - Using AI to analyze the Epstein files40:10 - The messiness of large health data sets46:00 - Immigration policy data analysis49:06 - Medicaid fraud and the limits of legal definitions56:20 - Advice to physicians on AI01:03:10 - The future of health policy research in the AI era@anish_koka and @drdigiorgio@drsloungepod🎧 Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1489323962🎧 Spotify: https://open.spotify.com/show/7vE4aCMpVHnSGwuOHiGVLp▶️ YouTube: https://www.youtube.com/@TheDoctorsLoungeResources:Kevin Bass's case documentation site: https://case.kevinnbass.comKevin Bass on Substack: https://www.kevinnbass.comKevin Bass on X: @kevinnbassKevin's original Newsweek op-ed (Jan. 2023): https://www.newsweek.com/its-time-scientific-community-admit-we-were-wrong-about-coivd-it-cost-lives-opinion-1776630Kevin's Epoch Times essay on his dismissal: https://www.theepochtimes.com/opinion/how-my-medical-school-scandalously-dismissed-me-5580841 | — | ||||||
| 3/9/26 | ![]() The Shah's Spleen, Quality Metrics, Health Insurance & the FDA | Dr. Anish Koka and Dr. Anthony DiGiorgio open with the little-known medical story behind the death of the Shah of Iran — how Mohammed Reza Pahlavi came to be operated on in Cairo in 1980 by legendary cardiovascular surgeon Michael DeBakey, and how the "comforting explanation" bias may have contributed to his death from a post-operative abscess rather than his underlying cancer. The case, drawn from a piece by Dr. Li Zhao (NYU Langone), launches a broader conversation about anchoring bias in medicine and the cognitive traps all clinicians face. From there, the hosts turn to the quality metric industrial complex — MIPS, the new low back pain ambulatory model threatening a 12% Medicare penalty for spine surgeons, the hospital readmission program's documented mortality spike, and how 2,266 CMS metrics are costing billions while failing patients. They close with a NEJM perspectives piece from Harvard Business School's Leemore Daphne on health insurance consolidation and her surprisingly free-market prescriptions for reform.Chapters00:00 Introduction02:00 The Shah of Iran — Political Background03:45 The Shah's Leukemia and Michael DeBakey's 1980 Surgery06:30 A Spleen the Size of a Football08:00 The Decision Not to Drain — And Its Consequences10:00 The Comforting Explanation Bias12:30 Subspecialization Matters — The Most Famous Surgeon Isn't Always the Right One14:45 Anchoring Bias in Clinical Medicine17:00 Modern Imaging and Residents as Checks on Bias18:30 Surgeons, Complications, and the M&M Conference21:00 Segue: Judging Doctors by Stats22:30 The Origins of Quality Metrics — Donabedian 196624:00 MIPS and How It Actually Works26:00 The New Back Pain Ambulatory Specialty Model — A 12% Penalty28:00 Evidence That Metrics Harm Patients: Hospital Readmission Reduction Program30:30 Obstetrics and the C-Section Penalty31:30 Press Ganey and the Cafeteria Problem33:00 Risk Adjustment Gaming — 40% Margin Increase from Coder Rounding38:00 2,266 Metrics and 108,000 Person-Hours at Johns Hopkins40:00 Why Doctors Leave Medicare42:00 What Good Metrics Could Look Like — Dr. DiGiorgio's JAMA Proposal44:00 Health Insurance Consolidation — NEJM Perspectives50:30 FDA, Vinay Prasad, and the WSJ Retraction55:00 Next Week: Kevin BassSubscribe to The Doctor's Lounge: Apple Podcasts | Spotify | YouTube Follow the Show: X: @DrsLoungePod Co-hosts: @anish_koka | @drdigiorgio | — | ||||||
| 2/28/26 | ![]() Dr. Mary Talley Bowden Battles the Health System | In this conversation, Dr. Mary Talley Bowden shares her experiences as an independent physician during the COVID-19 pandemic, detailing her courageous battle against health systems and the Texas Medical Board. She discusses the challenges faced by healthcare professionals, the impact of politics on medical practices, and the importance of patient care and medical freedom. Dr. Bowden emphasizes the need for changes in healthcare policies, including the repeal of mandates and the promotion of alternative treatments like ivermectin. Her personal philosophy and motivation to fight for her patients shine through as she navigates the complexities of the healthcare system.Chapters00:00 Introduction to Dr. Mary Talley Bowden02:17 Dr. Bowden's Courageous Battle Against Health Systems06:01 The Role of Telemedicine and Ivermectin in COVID Treatment11:37 Legal Battles and Hospital Privileges17:03 The Texas Medical Board and Its Controversies22:21 Political Dynamics in Texas Healthcare27:22 The Future of Independent Medicine32:19 The Impact of COVID Vaccines on Patients37:26 Ethical Concerns and Medical Mandates40:40 Critique of Public Health Figures46:03 The Role of Independent Physicians50:58 Future of Healthcare and Patient EmpowermentAbout Dr. Mary Talley Bowden:Dr. Mary Talley Bowden is a Stanford-trained ENT physician running a solo, third-party-free practice in Houston, Texas. She became nationally known during COVID for continuing to see patients, offering early treatment, and publicly opposing vaccine mandates. She is currently in ongoing litigation with both Houston Methodist and the Texas Medical Board.Subscribe to The Doctor's Lounge: Apple Podcasts | Spotify | YouTube | RSSFollow the Show: X: @DrsLoungePodCo-hosts: @anish_koka | @drdanchoi | @dutchrojas | @sdixitmd | | — | ||||||
| 2/21/26 | ![]() The Week in Review and Understanding the Medicaid Data Dump with Samir Unni | Episode Title: The Medicaid Data Dump: $1.7 Billion in Billing From Shell Companies and Why Nobody Stopped ItGuest: Samir Unni | Biomedical Engineer, former Palantir healthcare data lead, currently working on federal data modernization effortsChapters00:00 Introduction and Technical Difficulties02:47 Reflections on Jay Bhattacharya's Insights06:04 Navigating Polarization in Science08:50 Moderna's Flu Vaccine Controversy11:56 Understanding the FDA's Refusal to File14:58 The Medicaid Data Dump and Its Implications17:50 Duplicate Payments in Medicaid20:59 The Role of Transparency in Healthcare24:01 Home Health Services and Fraud Risks42:57 Understanding Fraud in Government Billing46:51 Political Ramifications of Home Health Agencies50:53 Analyzing Data for Fraud Detection56:30 Incentives and Accountability in Healthcare01:01:52 The Role of Technology in Fraud Prevention01:12:32 Legislative Solutions to Healthcare FraudResources Mentioned:Samir Unni's viral Medicaid data thread (@SamirUnni on X)CMS TMSIS Medicaid provider-level data releaseAnish Koka's deep dive on Fluarix clinical efficacyHHS Office of Inspector General excluded individuals/entities listDr. Mandrola's posts on the Moderna/FDA controversyAlex Berenson's report on autism behavioral therapy billing trendsAbout Samir Unni:Samir Unni is a biomedical engineer who has spent over a decade working at the intersection of healthcare and data analytics. He previously served as a lead at Palantir working with government and healthcare organizations, and is now focused on modernizing how the federal government leverages AI and data tools to identify waste and fraud in public health programs.Subscribe to The Doctor's Lounge: Apple Podcasts | Spotify | YouTube | RSSFollow the Show: X: @drsloungepodCo-hosts: @anish_koka | @drdanchoi | @dutchrojas | @sdixitmd | @DrDiGiorgio | — | ||||||
| 2/14/26 | ![]() NIH Director Jay Bhattacharya | In this engaging conversation, Dr. Jay Bhattacharya discusses his unique perspective as a health economist and the impact of his training on his approach to public health, particularly during the COVID-19 pandemic. He reflects on the Great Barrington Declaration, the importance of dissent in science, and the need for reform within the NIH to foster innovation and address the replication crisis in research. Dr. Bhattacharya emphasizes the necessity of a culture shift in science, advocating for transparency and rigorous inquiry into public health issues, including vaccines and chronic diseases.TakeawaysDr. Bhattacharya's background in economics shapes his approach to health policy.The COVID-19 pandemic highlighted the importance of considering trade-offs in public health decisions.Dissent in science is crucial for progress and innovation.The Great Barrington Declaration challenged the prevailing public health narrative during the pandemic.The NIH must adapt to foster a culture of questioning and innovation.Addressing the replication crisis is essential for restoring trust in scientific research.Public health responses must be transparent and trustworthy to gain public confidence.Raising the evidentiary bar for vaccines is necessary to ensure safety and efficacy.The NIH's role in funding research should focus on improving health outcomes.A second scientific revolution is needed to shift the power dynamics in research. TitlesNavigating Public Health: Insights from Dr. Jay BhattacharyaThe Economics of Health Policy: A Conversation with Dr. BhattacharyaChapters00:00 Introduction to Dr. Jay Bhattacharya03:18 The Influence of Economics on Health Policy06:23 Unique Perspectives During the COVID-19 Pandemic10:12 The Role of Authority in Public Health Decisions13:08 The Great Barrington Declaration and Its Impact16:27 Challenges to Scientific Consensus19:08 Leading the NIH: An Economic Perspective22:33 Addressing the Replication Crisis in Science36:56 Addressing Scientific Stagnation and Replication Crisis43:42 Fostering a Culture of Dissent in Science52:56 Setting Research Priorities for Public Health59:58 Navigating Vaccine Safety and Public TrustSubscribe to The Doctor's Lounge: Apple Podcasts | Spotify | YouTube | RSSFollow the Show: X: @drsloungepodCo-hosts: @anish_koka | @drdanchoi | @dutchrojas | @sdixitmd | @DrDiGiorgio | — | ||||||
Showing 25 of 66
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.

